Artivion provides $25M additional loans to Endospan, reduces purchase option to $135M net

ARTIVION, INC.

Up to $25M in three tranches ($7M upfront) to fund NEXUS FDA approval; loan secured by first-priority lien.
Purchase option upfront payment reduced from $250M to $175M; net to $135M after loan offset.
$100M minimum earnout eliminated; earnout now 2.5x incremental year-2 revenue (max $200M).
Company does not expect material impact on FY2024 guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.